| Timothy Lynn Lindemann, MD | |
|
100 N Academy Ave, Danville, PA 17822-1625 | |
| (570) 271-6429 | |
| Not Available |
| Full Name | Timothy Lynn Lindemann |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 23 Years |
| Location | 100 N Academy Ave, Danville, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750324307 | NPI | - | NPPES |
| 8P9633 | Other | TX | BCBS OF TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | MD422865 (Pennsylvania) | Primary |
| 207YX0602X | Otolaryngology - Otolaryngic Allergy | MD422865 (Pennsylvania) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Geisinger Medical Center | Danville, PA | Hospital |
| Geisinger-bloomsburg Hospital | Bloomsburg, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Geisinger Clinic | 5395657001 | 2866 |
News Archive
Sevocity, the leader in cloud-based Electronic Health Records, today announced that Sevocity v11.1 has achieved full certification through the Certification Commission for Health Information Technology (CCHIT) and is a CCHIT Certified 2011 Ambulatory EHR.
PharmAthene, Inc. announced today that it has achieved significant progress in the development of its second generation anthrax vaccine, SparVax.
Affymax, Inc. today reported financial results for the second quarter ended June 30, 2010. Net income for the second quarter of 2010 was $17.3 million compared to a net loss of $22.1 million for the second quarter of 2009. The company received milestone payments of $30.0 million from Takeda Pharmaceutical Company Limited for database lock of the Hematide/peginesatide Phase 3 clinical trials.
BioSante Pharmaceuticals, Inc., today announced completion of enrollment in its ongoing LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.
A practical resource-based public health approach for the rapid initiation of antiretroviral therapy in HIV-infected individuals living in low- and middle-income countries could save thousands of lives, according to an Essay published January 15 in the open-access journal PLOS Medicine by Mark Tenforde of the University of Washington School of Medicine, and colleagues.
› Verified 2 days ago
| Entity Name | Geisinger Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366493868 PECOS PAC ID: 5395657001 Enrollment ID: O20040130000518 |
News Archive
Sevocity, the leader in cloud-based Electronic Health Records, today announced that Sevocity v11.1 has achieved full certification through the Certification Commission for Health Information Technology (CCHIT) and is a CCHIT Certified 2011 Ambulatory EHR.
PharmAthene, Inc. announced today that it has achieved significant progress in the development of its second generation anthrax vaccine, SparVax.
Affymax, Inc. today reported financial results for the second quarter ended June 30, 2010. Net income for the second quarter of 2010 was $17.3 million compared to a net loss of $22.1 million for the second quarter of 2009. The company received milestone payments of $30.0 million from Takeda Pharmaceutical Company Limited for database lock of the Hematide/peginesatide Phase 3 clinical trials.
BioSante Pharmaceuticals, Inc., today announced completion of enrollment in its ongoing LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.
A practical resource-based public health approach for the rapid initiation of antiretroviral therapy in HIV-infected individuals living in low- and middle-income countries could save thousands of lives, according to an Essay published January 15 in the open-access journal PLOS Medicine by Mark Tenforde of the University of Washington School of Medicine, and colleagues.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Timothy Lynn Lindemann, MD 100 N Academy Ave, Danville, PA 17822-4903 Ph: (570) 271-6144 | Timothy Lynn Lindemann, MD 100 N Academy Ave, Danville, PA 17822-1625 Ph: (570) 271-6429 |
News Archive
Sevocity, the leader in cloud-based Electronic Health Records, today announced that Sevocity v11.1 has achieved full certification through the Certification Commission for Health Information Technology (CCHIT) and is a CCHIT Certified 2011 Ambulatory EHR.
PharmAthene, Inc. announced today that it has achieved significant progress in the development of its second generation anthrax vaccine, SparVax.
Affymax, Inc. today reported financial results for the second quarter ended June 30, 2010. Net income for the second quarter of 2010 was $17.3 million compared to a net loss of $22.1 million for the second quarter of 2009. The company received milestone payments of $30.0 million from Takeda Pharmaceutical Company Limited for database lock of the Hematide/peginesatide Phase 3 clinical trials.
BioSante Pharmaceuticals, Inc., today announced completion of enrollment in its ongoing LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.
A practical resource-based public health approach for the rapid initiation of antiretroviral therapy in HIV-infected individuals living in low- and middle-income countries could save thousands of lives, according to an Essay published January 15 in the open-access journal PLOS Medicine by Mark Tenforde of the University of Washington School of Medicine, and colleagues.
› Verified 2 days ago
Dr. Thorsen Wayne Haugen, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6429 Fax: 570-271-6854 | |
Aileen Wertz, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6429 Fax: 570-271-6854 | |
Dr. Jeremy Alexander Mock, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6429 Fax: 570-271-6854 | |
Linda Gage-white, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6429 Fax: 570-271-6854 | |
Jeff Wong, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6211 | |
Dr. Joseph Scott Greene, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6429 | |
James Barrese, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-214-5681 |